论文部分内容阅读
目的:观察奥氮平联合心脑欣丸对双相情感障碍躁狂发作患者认知功能的改善作用以及对血清白细胞介素1β(IL-1β)、肿瘤坏死因子α(TNF-α)、IL-10水平的影响。方法:筛选2018年1－12月在温州康宁医院就诊的双相情感障碍躁狂发作患者88例，按照随机数字表法将患者分为对照组和观察组各44例。对照组口服奥氮平片，首剂5 mg/d，直至20 mg/d维持服用。观察组在对照组治疗基础上口服心脑欣丸，5丸/次，2次/d。连续治疗2个月，比较两组患者倍克-拉范森躁狂量表(BRMS)、生活质量健康状况调查简表(SF-36)、认知功能评分、临床疗效以及IL-1β、TNF-α、IL-10水平。结果:治疗后：观察组患者的BRMS评分(9.18±1.31)分，显著低于对照组的(13.51±2.08)分(n t＝6.833，n P＝0.000)；SF-36评分(329.98±35.31)分，明显高于对照组的(293.78±31.49)分(n t＝56.778，n P＝0.000)；观察组患者持续应答数评分(31.34±5.52)分、持续错误数评分(8.39±1.08)分、错误应答数评分(43.31±6.03)分，均明显低于对照组的(36.31±5.16)分(n t＝7.880，n P＝0.000)、(10.61±1.75)分(n t＝5.533，n P＝0.000)、(45.90±6.23)分(n t＝5.003，n P＝0.000)；完成分类数评分(4.14±0.51)分，明显高于对照组的(3.09±0.39)分(n t＝5.541，n P＝0.000)；观察组总有效率[95.35%(41/43)]显著高于对照组[75.61%(31/41)](χn 2＝5.164，n P＝0.023)；观察组血清IL-1β[(2.56±0.34)ng/L]、TNF-α[(8.33±1.05)ng/L]，显著低于对照组[(3.51±0.44)ng/L](n t＝6.334，n P＝0.000)、[(11.93±1.63)ng/L](n t＝7.003，n P＝0.000)，IL-10[(269.31±28.64)ng/L]明显高于对照组[(251.89±27.46)ng/L](n t＝11.351，n P＝0.000)。n 结论:奥氮平联合心脑欣丸可有效改善双相情感障碍躁狂发作患者的症状体征、生活质量、认知功能，提高临床疗效，调节血清IL-1β、TNF-α、IL-10水平可能与其疗效有关。“,”Objective:To observe the improvement effect of olanzapine combined with Xinnaoxin pill on cognitive function in patients with bipolar disorder manic episode, and its influence on serum levels of interleukin(IL)-1β, tumor necrosis factor(TNF)-α and IL-10.Methods:From January 2018 to December 2018, 88 patients with bipolar disorder manic episode admitted to Wenzhou Kangning Hospital were screened and divided into control group and observation group according to the random number table method, with 44 cases in each group.The control group was orally given olanzapine tablets, with the first dose of 5 mg/d, up to 20 mg/d, and kept taking.On the basis of the control group, the observation group orally received Xinnaoxin pills with 5 pills per time and 2 times/d.After treatment for 2 months, the scores of the Beck-lavenson manic scale(BRMS), quality of life health survey summary(SF-36), cognitive function, the efficacy, and serum levels of IL-1β, TNF-α, IL-10 were compared in the two groups.Results:After treatment, the BRMS score of the observation group[(9.18±1.31)points] was significantly lower than that of the control group[(13.51±2.08)points](n t=6.833, n P=0.000), the SF-36 score of the observation group[(329.98±35.31)points] was significantly higher than that of the control group[(293.78±31.49)points](n t=56.778, n P=0.000). The number of sustained responses (31.34±5.52), sustained errors (8.39±1.08), and false responses (43.31±6.03) in the observation group were significantly lower than those in the control group[(36.31±5.16), (10.61±1.75), (45.90±6.23)](n t=7.880, 5.533, 5.003, all n P=0.000), and the number of completed classification of the observation group(4.14±0.51) was significantly higher than that in the control group(3.09±0.39)(n t=5.541, n P=0.000). The total effective rate in the observation group(95.35%) was significantly higher than that in the control group(75.61%)(χn 2=5.164, n P=0.023). The serum levels of IL-1β[(2.56±0.34)ng/L] and TNF-α [(8.33±1.05) ng/L] in the observation group were significantly lower than those in the control group[(3.51±0.44)ng/L, (11.93±1.63)ng/L](n t=6.334, 7.003, all n P=0.000), and the serum level of IL-10 in the observation group [(269.31±28.64)ng/L] was significantly higher than that in the control group [(251.89±27.46)ng/L](n t=11.351, n P=0.000).n Conclusion:Olanzapine combined with Xinnaoxin pill in the treatment of bipolar disorder manic episode can effectively improve symptoms and signs, quality of life, cognitive function, increase the efficacy, and regulation of serum levels of IL-1β, TNF-α and IL-10 may be related with the efficacy.